elicit
antibodi
potent
broad
neutral
activ
hiv
immun
remain
challeng
sever
monoclon
antibodi
mab
isol
human
infect
exhibit
activ
vaccin
immunogen
base
structur
contain
epitop
success
elicit
known
broadli
neutral
mab
bnmab
immunoglobulin
ig
gs
igg
highli
somat
hypermut
could
imped
elicit
ig
ms
igm
averag
significantli
less
diverg
germlin
antibodi
relev
develop
vaccin
immunogen
underexplor
compar
igg
describ
identif
character
sever
human
igmderiv
mab
select
larg
phagedisplay
naiv
human
antibodi
librari
construct
blood
lymph
node
spleen
healthi
donor
antibodi
bound
high
affin
recombin
envelop
glycoprotein
env
isol
differ
clade
enhanc
neutral
infect
primari
isol
use
coreceptor
neutral
isol
test
although
weakli
one
antibodi
rel
low
degre
somat
hypermut
extens
character
bound
highli
conserv
region
virus
partial
overlap
coreceptor
bind
site
close
overlap
bind
site
result
suggest
exist
conserv
structur
could
direct
immun
respons
nonneutr
even
enhanc
antibodi
may
repres
strategi
use
viru
escap
neutral
immun
respons
studi
show
whether
strategi
play
role
hiv
infect
human
import
role
could
mechan
infect
enhanc
newli
identifi
mab
could
use
reagent
character
conserv
nonneutr
weakli
neutral
enhanc
epitop
modifi
remov
candid
vaccin
immunogen
abil
human
immunodefici
viru
type
rapidli
gener
mutant
evad
immun
respons
major
obstacl
develop
protect
prophylact
vaccin
therefor
candid
vaccin
immunogen
must
capabl
elicit
broadli
neutral
antibodi
bnab
inhibit
virus
differ
genet
subtyp
sever
human
monoclon
antibodi
hmab
exhibit
potent
broad
neutral
activ
vitro
prevent
infect
anim
model
bnab
target
structur
envelop
glycoprotein
env
crucial
viruscel
fusion
therefor
env
variou
format
potenti
candid
immunogen
evalu
anim
model
human
clinic
trial
howev
neutral
efficaci
result
sera
broad
bnab
achiev
empir
use
env
immunogen
suggest
character
epitop
bnab
could
help
design
vaccin
immunogen
would
abl
elicit
bnab
similar
antibodi
vivo
although
approach
vigor
pursu
none
immunogen
design
yet
effici
elicit
neutral
antibodi
broad
specif
igm
initi
antibodi
host
gener
infecti
agent
antigen
encount
activ
igmexpress
b
cell
provid
impetu
vivo
igmtoigg
isotyp
switch
result
product
highaffin
neutral
nonneutr
antibodi
therefor
import
investig
human
igm
repertoir
envspecif
antibodi
understand
interact
env
impact
viral
infect
could
help
design
effect
immunogen
previou
attempt
select
hivspecif
antibodi
use
nonimmun
librari
result
antibodi
modest
neutral
activ
limit
breadth
neutral
studi
sever
group
show
human
igm
antibodi
play
import
role
shape
humor
immun
also
induc
cellmedi
respons
pentamer
bind
natur
well
effici
activ
activ
complement
et
al
indic
vivo
igmtoigg
isotyp
switch
affin
matur
may
import
protect
longterm
surviv
certain
individu
sheppard
et
al
demonstr
complementdeactiv
serum
healthi
volunt
immun
clade
c
exhibit
igmassoci
neutral
activ
significantli
enhanc
presenc
fresh
normal
human
serum
sourc
complement
bomsel
et
al
show
human
igm
monoclon
antibodi
block
transcytot
rout
hiv
mucos
transmiss
vitro
studi
describ
identif
character
sever
human
igmderiv
mab
select
phagedisplay
naiv
human
antibodi
librari
construct
healthi
donor
antibodi
high
affin
crossreact
differ
clade
either
neutral
enhanc
weakli
entri
virion
pseudotyp
env
primari
isol
data
provid
addit
insight
possibl
immun
respons
infect
viral
envbas
immun
could
elicit
help
design
candid
vaccin
immunogen
elicit
potent
neutral
earli
transmit
viru
larg
member
phagedisplay
naiv
human
antibodi
antigenbind
fragment
fab
librari
design
construct
peripher
blood
b
cell
healthi
donor
spleen
healthi
donor
lymph
node
healthi
donor
describ
materi
method
phagemid
use
librari
construct
synthes
briefli
describ
previous
approxim
estim
sequenc
divers
clone
randomli
select
librari
sequenc
ident
sequenc
heavi
light
chain
found
clone
product
clone
kappa
light
chain
lambda
light
chain
pan
sever
env
human
cancerrel
antigen
signific
enrich
obtain
pan
data
shown
result
indic
qualiti
librari
like
good
identifi
human
igmderiv
antibodi
specif
env
pan
clade
b
isol
one
select
antibodi
clone
contain
tga
stop
codon
begin
light
chain
due
nucleotid
delet
result
readingfram
shift
heavi
chain
variabl
domain
vh
design
differ
closest
human
germlin
sequenc
mutat
distribut
framework
fr
complementar
determin
region
cdr
figur
contain
mutat
nucleotid
sequenc
variabl
v
region
result
mutat
amino
acid
sequenc
correct
read
frame
light
chain
sitedirect
mutagenesi
correct
antibodi
design
express
high
level
bacteria
fab
fab
specif
bound
rel
high
affin
ec
nm
clade
c
isol
ec
nm
antibodi
initi
select
function
heavi
chainonli
antibodi
hypothes
bind
activ
attribut
mainli
heavi
chain
antibodi
heavi
chain
could
pair
light
chain
deriv
differ
germlin
retain
crossreact
env
clone
isol
antibodi
domain
found
highli
solubl
stabl
monomer
express
high
level
bacteria
agreement
hypothesi
specif
bound
although
low
affin
ec
nm
construct
light
chainshuffl
fab
librari
member
base
heavi
chain
increas
probabl
select
crossreact
antibodi
librari
pan
sequenti
clade
f
isol
five
uniqu
clone
identifi
contain
exclus
lambda
light
chain
figur
bound
ec
rang
nm
tabl
signific
bind
unrel
antigen
bovin
serum
albumin
bsa
observ
data
shown
one
antibodi
also
bound
high
affin
env
three
clade
b
isol
bal
jrfl
con
result
suggest
possibl
select
antibodi
target
conserv
epitop
test
whether
five
newli
select
antibodi
capabl
neutral
primari
isol
use
virus
pseudotyp
env
isol
repres
clade
b
c
use
either
coreceptor
none
antibodi
exhibit
potent
broadli
neutral
activ
four
antibodi
fab
enhanc
infect
bal
even
low
antibodi
concentr
posit
control
antibodi
show
effici
neutral
neg
control
antibodi
affect
entri
figur
enhanc
infect
anoth
clade
b
primari
isol
jrfl
high
concentr
figur
interestingli
three
antibodi
enhanc
significantli
infect
bal
weakli
neutral
iiib
tcla
clade
b
isol
figur
find
whether
activ
antibodi
relat
antibodi
size
viral
infect
could
affect
crosslink
env
gener
singlechain
fv
fragment
scfv
scfv
human
fcfusion
protein
scfv
select
character
light
chain
rel
less
diverg
germlin
figur
one
contain
somat
mutat
light
chain
bal
test
enhanc
activ
scfv
compar
fab
slightli
lower
data
shown
data
indic
antibodi
access
epitop
sizerestrict
bival
fc
fusion
protein
strengthen
antibodi
activ
probabl
due
avid
effect
abil
modul
infect
vitro
test
six
addit
clade
b
isol
isol
clade
clade
c
respect
figur
enhanc
observ
jrcsf
clade
b
low
concentr
enhanc
decreas
increas
antibodi
concentr
also
confer
slight
enhanc
infect
jrfl
clade
b
clade
nm
antibodi
concentr
neutral
clade
b
isol
iiib
also
neutral
clade
b
isol
display
independ
moder
neutral
sensit
well
clade
c
isol
signific
antibodi
activ
observ
dual
tropic
clade
b
isol
result
indic
antibodi
activ
term
neutral
enhanc
vari
differ
isol
test
significantli
correl
coreceptor
usag
depend
virus
entri
antibodi
two
antibodi
b
bind
bal
bal
respect
irrelev
human
antibodi
use
neg
control
approxim
local
antibodi
epitop
begin
elucid
underli
mechan
antibodi
neutral
enhanc
activ
measur
antibodi
bind
env
differ
isol
alon
complex
well
antibodi
competit
wellcharacter
antibodi
bound
singlechain
polypeptid
analogu
complex
bal
threefold
higher
affin
nm
bal
nm
alon
measur
elisa
figur
react
suggest
antibodi
target
structur
outsid
site
could
undergo
conform
chang
conform
chang
bal
bind
confirm
bnab
exhibit
dramat
higher
bind
bal
bal
figur
find
whether
antibodi
bound
convent
epitop
use
con
synthet
env
design
align
consensu
env
sequenc
group
env
design
compos
shorter
loop
therefor
might
expos
region
around
variabl
loop
might
contain
conserv
neutral
determin
howev
epitop
repres
epitop
still
complet
hidden
con
bind
absenc
bind
high
affin
presenc
figur
howev
show
compar
bind
con
without
figur
suggest
antibodi
precis
target
epitop
structur
although
direct
pocket
strongli
compet
bnab
scfv
bind
surfac
larger
figur
also
compet
although
weakli
two
antibodi
scfv
figur
result
suggest
epitop
close
proxim
coreceptorbind
site
corb
overlap
epitop
figur
figur
schemat
represent
epitop
gray
blue
red
white
area
denot
corb
respect
epitop
long
dashdot
circl
left
antibodi
indic
comparison
area
dash
circl
right
denot
corb
isol
could
partial
overlap
epitop
estim
possibl
rapid
elicit
antibodi
vivo
immunogen
administ
gener
germlinelik
scfv
scfv
measur
bind
env
differ
isol
presenc
absenc
obviou
interact
observ
scfv
sever
env
bound
origin
test
data
shown
previou
studi
show
bind
activ
antibodi
form
fab
scfv
could
increas
thousand
time
convert
dimer
format
igg
therefor
fuse
scfv
fc
portion
human
gain
possibl
avid
effect
still
fcfusion
protein
scfv
show
measur
bind
env
without
figur
result
suggest
signific
somat
diversif
requir
correspond
germlin
antibodi
achiev
recognit
epitop
also
indic
individu
certain
igm
antibodi
could
undergo
somat
hypermut
rel
highaffin
binder
env
absenc
infect
immun
env
figur
bind
germlinelik
antibodi
differ
absenc
presenc
origin
antibodi
use
posit
control
vaccin
base
recombin
env
fail
prevent
viral
infect
human
efficaci
trial
like
inabl
elicit
neutral
antibodi
broad
enough
combat
extrem
high
variabl
viru
recent
success
report
modest
need
repeat
examin
date
sever
bnab
isol
patient
suggest
difficulti
elicit
antibodi
vivo
howev
presenc
epitop
recogn
bnab
env
argu
still
potenti
templat
vaccin
design
differ
strategi
aim
improv
present
neutral
epitop
rigor
pursu
analysi
structur
env
show
surfac
hidden
humor
immun
respons
glycosyl
oligomer
occlus
corb
also
flank
loop
structur
may
limit
access
antibodi
gener
human
immun
system
therefor
one
strategi
focus
use
modifi
env
variabl
loop
delet
glycosyl
remov
order
increas
exposur
neutral
epitop
base
find
neutral
capac
antibodi
associ
abil
bind
nativ
trimer
env
viru
correl
bind
isol
monomer
env
anoth
strategi
focus
preserv
reconstruct
function
trimer
env
essenti
concept
immun
close
mimic
function
trimer
improv
chanc
elicit
neutral
antibodi
yet
anoth
strategi
use
fusion
intermedi
form
viru
entri
mimic
entri
initi
bind
viral
receptor
coreceptor
target
cell
surfac
interact
lead
intermedi
env
conform
may
includ
conserv
structur
use
vaccin
design
howev
elicit
desir
level
breath
neutral
antibodi
immunogen
gener
base
strategi
achiev
modif
env
base
sole
analysi
interact
neutral
antibodi
suffici
creat
effect
vaccin
propos
inher
capac
human
immun
system
respons
infect
explor
hypothes
investig
human
igm
repertoir
envspecif
antibodi
understand
react
env
evolv
impact
viral
infect
would
help
design
effect
immunogen
previous
found
igmbas
respons
confer
substanti
effect
infect
especi
relev
context
acut
infect
studi
describ
identif
character
sever
highaffin
human
igmderiv
mab
phagedisplay
naiv
human
antibodi
librari
construct
healthi
donor
although
potenc
vitro
appear
minor
role
could
play
mediat
infect
vivo
underestim
igm
antibodi
highli
effect
activ
complement
system
destroy
viru
infect
cell
antibodi
select
studi
target
highli
conserv
region
close
proxim
corb
two
region
vital
viru
entri
harbor
neutral
epitop
evolv
strategi
steric
occlus
protect
humor
immun
suggest
possibl
high
immunogen
conserv
nonneutr
epitop
antibodi
could
divert
immun
system
respons
neutral
epitop
recent
studi
show
crossreact
nonneutr
antibodi
igm
igg
elicit
immun
mice
recombin
suggest
possibl
human
antibodi
select
less
diverg
total
amino
acid
mutat
v
gene
product
heavi
light
chain
figur
known
bnab
contain
extens
somat
mutat
averag
mutat
compar
germlin
antibodi
data
shown
could
easili
elicit
addit
antibodi
could
directli
block
access
neutral
antibodi
gener
human
immun
system
especi
target
corb
support
find
partial
revers
neutral
antibodi
data
shown
result
support
previou
proposit
reduc
immunogen
unwant
epitop
use
immunogen
found
closest
germlinelik
antibodi
bind
env
figur
observ
similar
lack
bind
germlinelik
env
moreov
found
lack
highaffin
binder
env
germlinelik
antibodi
repertoir
human
cord
blood
wherea
highaffin
antibodi
human
infecti
agent
includ
sar
coronaviru
henipavirus
could
easili
select
weizao
chen
emili
streaker
dimit
dimitrov
prepar
identifi
antibodi
sar
coronaviru
protein
exhibit
nanomolar
affin
close
germlin
sequenc
analyz
previous
identifi
antibodi
sequenc
found
crossreact
neutral
antibodi
highli
diversifi
germlin
sequenc
contrast
antibodi
sar
coronaviru
henipavirus
limit
number
mutat
result
indic
extens
somat
mutat
could
requir
highaffin
bind
conserv
env
structur
one
could
specul
matur
pathway
antibodi
initi
immunogen
differ
env
immunogen
could
use
combin
envbas
immunogen
guid
immun
system
elicit
potent
bnab
addit
somat
hypermut
select
line
proposit
elicit
bnab
use
one
primari
immunogen
differ
env
lead
intermedi
matur
pathway
subsequ
somat
hypermut
matur
bnab
except
convent
antigenantibodi
interact
also
bind
small
popul
human
antibodi
contain
product
mainli
gene
famili
exhibit
superantigen
properti
activ
human
b
cell
express
antibodi
cellular
membran
core
motif
superantigenbind
site
sb
discontinu
structur
span
variabl
domain
aminotermin
region
flank
constant
domain
determin
antibodi
vh
domain
critic
bind
clear
yet
put
import
region
identifi
model
studi
show
potenti
contact
residu
locat
face
vh
opposit
interfac
interact
light
chain
posit
also
influenc
bind
moreov
antibodi
vh
gene
show
similar
germlin
suggest
somat
hypermut
may
advers
effect
bind
antibodi
describ
studi
contain
gene
product
figur
therefor
high
bind
could
due
superantigenlik
interact
howev
result
show
isol
vh
antibodi
bound
affin
ec
nm
much
lower
ec
nm
fab
addit
epitop
one
antibodi
map
structur
close
proxim
corb
defin
sb
result
suggest
major
bind
activ
select
antibodi
contribut
convent
antigenantibodi
recognit
one
note
antibodi
may
repres
nativ
one
select
phage
librari
heavi
light
chain
antibodi
randomli
recombin
howev
previou
studi
shown
select
highaffin
antibodi
librari
result
antibodi
ident
similar
occur
host
librari
made
shown
least
system
antigen
select
antibodi
autoantibodi
thyroid
peroxidas
tpo
larg
random
phage
librari
pair
small
librari
cognat
pair
preserv
pair
light
heavi
chain
promiscu
studi
chapal
et
al
directli
demonstr
antibodi
deriv
combinatori
librari
like
repres
vivo
pair
lead
high
affin
antibodi
fragment
mimick
bind
serum
autoantibodi
tpo
de
wildt
et
al
analyz
cognat
pair
heavi
light
chain
variabl
domain
human
igg
b
cell
peripher
blood
establish
pair
larg
random
antibodi
select
origin
larg
famili
gene
heavi
chain
light
chain
figur
importantli
pair
two
found
limit
number
truli
human
antibodi
previous
analyz
moreov
eg
antibodi
rel
close
correspond
germlin
figur
data
suggest
possibl
elicit
antibodi
vivo
infect
immun
purchas
cell
atcc
cell
line
plasmid
use
express
variou
env
obtain
nation
institut
health
aid
research
refer
reagent
program
arrrp
recombin
produc
laboratori
bal
singlechain
fusion
protein
bal
kindli
provid
fout
institut
human
virolog
baltimor
current
profectu
baltimor
md
horseradish
peroxidas
hrp
conjug
antiflag
tag
antibodi
hrpconjug
antihuman
igg
fcspecif
antibodi
purchas
sigmaaldrich
st
loui
construct
use
phagemid
accord
report
protocol
sourc
amplif
antibodi
gene
fragment
commerci
purchas
poli
rna
bd
bioscienc
san
jose
ca
peripher
blood
b
cell
healthi
donor
spleen
three
donor
lymph
node
healthi
donor
respect
use
select
antibodi
antigen
conjug
magnet
bead
dynabead
epoxi
dynal
inc
new
hyde
park
ny
describ
previous
use
first
second
third
fourth
round
pan
respect
clone
specif
bound
identifi
third
fourth
round
use
monoclon
phage
elisa
mpelisa
describ
light
chainshuffl
fab
librari
member
construct
base
heavi
chain
light
chain
repertoir
also
harvest
naiv
human
fab
librari
member
construct
peripher
blood
b
cell
healthi
donor
addit
new
librari
pan
sequenti
two
differ
clade
sequenti
pan
use
first
third
round
respect
antigen
altern
second
fourth
round
respect
clone
bound
identifi
fourth
round
use
mpelisa
describ
follow
primer
use
ttt
cgc
tac
cgt
ggc
cca
gcc
ggc
cca
ggt
gca
gct
sens
agt
ttt
gtc
ggg
ccc
tag
gac
ggt
cag
ctt
antisens
construct
scfv
fulllength
origin
germlin
scfv
gene
fragment
synthes
genscript
piscataway
nj
digest
sfii
clone
gener
fcfusion
protein
scfv
gene
pcr
primer
amplifi
use
synthet
scfv
gene
fragment
templat
new
scfv
product
append
sfii
apai
restrict
site
side
digest
clone
psectagbfc
scfv
fab
express
e
coli
describ
previous
bacteri
pellet
collect
centrifug
g
min
resuspend
pb
ph
contain
millionunit
polymixin
b
sigmaaldrich
min
incub
rotat
rpm
room
temperatur
centrifug
g
min
supernat
use
purif
scfv
fab
immobil
metal
ion
affin
chromatographi
imac
use
ninta
resin
qiagen
valencia
ca
accord
manufactur
protocol
fcfusion
protein
express
free
style
cell
invitrogen
carlsbad
ca
use
transfect
free
style
cell
accord
instruct
manufactur
three
day
posttransfect
cultur
supernat
harvest
use
purif
use
nprotein
sepharos
fast
flow
ge
healthcarezcomx
piscataway
nj
bind
competit
elisa
perform
describ
previous
virus
pseudotyp
env
prepar
cotransfect
confluent
cell
construct
encod
env
use
polyfect
transfect
reagent
qiagen
accord
manufactur
instruct
pseudotyp
virus
obtain
h
centrifug
filtrat
cell
cultur
filter
neutral
virus
mix
differ
concentr
antibodi
h
mixtur
ad
use
dual
tropic
virus
cell
grown
well
plate
lumines
measur
h
use
brightglo
luciferas
assay
system
promega
madison
wi
lumicount
micropl
luminomet
turner
design
mean
rel
light
unit
rlu
duplic
well
determin
rel
infect
calcul
follow
formula
averag
rlu
antibodycontain
wellsaverag
rlu
virusonli
well
major
find
studi
identif
character
sever
human
igmderiv
mab
highli
conserv
epitop
antibodi
rare
investig
report
character
antibodi
dynam
epitop
could
provid
knowledg
addit
use
basic
understand
immun
respons
could
also
help
design
candid
vaccin
immunogen
elicit
potent
neutral
earli
transmit
viru
